293 related articles for article (PubMed ID: 27233924)
21. Threshold of toxicological concern (TTC) for developmental and reproductive toxicity of anticancer compounds.
Stanard B; Dolan DG; Hanneman W; Legare M; Bercu JP
Regul Toxicol Pharmacol; 2015 Aug; 72(3):602-9. PubMed ID: 26025210
[TBL] [Abstract][Full Text] [Related]
22. Determination and application of the permitted daily exposure (PDE) for topical ocular drugs in multipurpose manufacturing facilities.
Lovsin Barle E; Bizec JC; Glogovac M; Gromek K; Winkler GC
Pharm Dev Technol; 2018 Mar; 23(3):225-230. PubMed ID: 28361586
[TBL] [Abstract][Full Text] [Related]
23. What to consider for a good quality PDE document?
Sehner C; Schwind M; Tuschl G; Lovsin Barle E
Pharm Dev Technol; 2019 Sep; 24(7):803-811. PubMed ID: 30865481
[TBL] [Abstract][Full Text] [Related]
24. Deriving harmonised permitted daily exposures (PDEs) for paracetamol (acetaminophen) CAS #: 103-90-2.
Gromek K; Hawkins W; Bernier T; Sehner C; Zeller E; Schwind M; Pfister T; Kohan M; Osadolor O; Glogovac M; Tuschl G; Dolan DG; Lovsin Barle E
Regul Toxicol Pharmacol; 2020 Aug; 115():104692. PubMed ID: 32522580
[TBL] [Abstract][Full Text] [Related]
25. Threshold of toxicological concern for chemical substances present in the diet: a practical tool for assessing the need for toxicity testing.
Kroes R; Galli C; Munro I; Schilter B; Tran L; Walker R; Würtzen G
Food Chem Toxicol; 2000; 38(2-3):255-312. PubMed ID: 10717364
[TBL] [Abstract][Full Text] [Related]
26. Principles of risk assessment for determining the safety of chemicals: recent assessment of residual solvents in drugs and di(2-ethylhexyl) phthalate.
Hasegawa R; Koizumi M; Hirose A
Congenit Anom (Kyoto); 2004 Jun; 44(2):51-9. PubMed ID: 15198717
[TBL] [Abstract][Full Text] [Related]
27. Challenges in setting permitted daily exposure limits for pharmaceuticals: A review.
Ahuja V; Krishnappa M
Int J Risk Saf Med; 2022; 33(1):49-64. PubMed ID: 34924402
[TBL] [Abstract][Full Text] [Related]
28. PDE concept for controlling cleaning agent residues in pharmaceuticals- A critical analysis.
Araya S; Pfister T; Gromek K; Hawkins W; Thomsen ST; Clemann N; Faltermann S; Wiesner L
Regul Toxicol Pharmacol; 2022 Feb; 128():105095. PubMed ID: 34890761
[TBL] [Abstract][Full Text] [Related]
29. Setting Occupational Exposure Limits for Genotoxic Substances in the Pharmaceutical Industry.
Lovsin Barle E; Winkler GC; Glowienke S; Elhajouji A; Nunic J; Martus HJ
Toxicol Sci; 2016 May; 151(1):2-9. PubMed ID: 27207978
[TBL] [Abstract][Full Text] [Related]
30. International landscape of limits and recommendations for occupational exposure to engineered nanomaterials.
Rodríguez-Ibarra C; Déciga-Alcaraz A; Ispanixtlahuatl-Meráz O; Medina-Reyes EI; Delgado-Buenrostro NL; Chirino YI
Toxicol Lett; 2020 Apr; 322():111-119. PubMed ID: 31981686
[TBL] [Abstract][Full Text] [Related]
31. Ethyl methanesulfonate toxicity in Viracept--a comprehensive human risk assessment based on threshold data for genotoxicity.
Müller L; Gocke E; Lavé T; Pfister T
Toxicol Lett; 2009 Nov; 190(3):317-29. PubMed ID: 19443141
[TBL] [Abstract][Full Text] [Related]
32. Approaches for setting occupational exposure limits in the pharmaceutical industry.
Ahuja V; Krishnappa M
J Appl Toxicol; 2022 Jan; 42(1):154-167. PubMed ID: 34254327
[TBL] [Abstract][Full Text] [Related]
33. Preventing Cross-Contamination during Lyophilization: GMP and Occupational Cleaning Requirements for Nonproduct and Indirect Product-Contact Parts.
Denk R; Flückiger A; Kisaka H; Krause S; Maeck R; Restetzki L; Schreiner A; Schulze R
PDA J Pharm Sci Technol; 2019; 73(5):487-495. PubMed ID: 31420508
[TBL] [Abstract][Full Text] [Related]
34. Use of the permitted daily exposure (PDE) concept for contaminants of intravitreal (IVT) drugs in multipurpose manufacturing facilities.
Lovsin Barle E; Pfister T; Fux C; Röthlisberger D; Jere D; Mahler HC
Regul Toxicol Pharmacol; 2019 Feb; 101():29-34. PubMed ID: 30367903
[TBL] [Abstract][Full Text] [Related]
35. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
36. Considerations for setting occupational exposure limits for novel pharmaceutical modalities.
Graham JC; Hillegass J; Schulze G
Regul Toxicol Pharmacol; 2020 Dec; 118():104813. PubMed ID: 33144077
[TBL] [Abstract][Full Text] [Related]
37. Environmental risk assessment of pharmaceutical drug substances--conceptual considerations.
Länge R; Dietrich D
Toxicol Lett; 2002 May; 131(1-2):97-104. PubMed ID: 11988362
[TBL] [Abstract][Full Text] [Related]
38. Using physiologically based pharmacokinetic modeling and benchmark dose methods to derive an occupational exposure limit for N-methylpyrrolidone.
Poet TS; Schlosser PM; Rodriguez CE; Parod RJ; Rodwell DE; Kirman CR
Regul Toxicol Pharmacol; 2016 Apr; 76():102-12. PubMed ID: 26776754
[TBL] [Abstract][Full Text] [Related]
39. Integration of a plasma protein binding factor to the Chemical-Specific Adjustment Factor (CSAF) for facilitating the estimation of uncertainties in interspecies extrapolations when deriving health-based exposure limits for active pharmaceutical ingredients: Investigation of recent drug datasets.
Poulin P; Arnett R
Regul Toxicol Pharmacol; 2017 Dec; 91():142-150. PubMed ID: 29107009
[TBL] [Abstract][Full Text] [Related]
40. Strategies for preventing occupational exposure to potent compounds.
Calhoun DM; Coler AB; Nieusma JL
Toxicol Mech Methods; 2011 Feb; 21(2):93-6. PubMed ID: 20507226
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
